Literature DB >> 20206418

3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.

Sugunadevi Sakkiah1, Sundarapandian Thangapandian, Shalini John, Yong Jung Kwon, Keun Woo Lee.   

Abstract

Chemical features based 3D pharmacophore models were developed for HSP90 based on the known inhibitors using Discovery Studio V2.1. An optimal pharmacophore model was brought forth and validated using a decoy set, external test set and Fischer's randomization method. The best five features pharmacophore model, Hypo1, includes two hydrogen bond acceptors, three hydrophobic features, which has the highest correlation coefficient (0.93), cost difference (73.88), low RMS (1.24), as well as it shows a high goodness of fit and enrichment factor. Hypo1 was used as a 3D query for virtual screening to retrieve potential inhibitors from Maybridge and Scaffold databases. The hit compounds were subsequently subjected to molecular docking studies and finally, 36 compounds were obtained based on consensus scoring function. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206418     DOI: 10.1016/j.ejmech.2010.01.016

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  21 in total

1.  An in silico protocol for identifying mTOR inhibitors from natural products.

Authors:  Lei Chen; Ling Wang; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2014-08-26       Impact factor: 2.943

2.  Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.

Authors:  Kuldeep K Roy; Supriya Singh; Anil K Saxena
Journal:  Mol Divers       Date:  2010-08-26       Impact factor: 2.943

3.  Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors.

Authors:  Wenting Tai; Tao Lu; Haoliang Yuan; Fengxiao Wang; Haichun Liu; Shuai Lu; Ying Leng; Weiwei Zhang; Yulei Jiang; Yadong Chen
Journal:  J Mol Model       Date:  2011-12-28       Impact factor: 1.810

4.  7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.

Authors:  Jiawang Liu; Thong T Nguyen; Patrick S Dupart; Jayalakshmi Sridhar; Xiaoyi Zhang; Naijue Zhu; Cheryl L Klein Stevens; Maryam Foroozesh
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

5.  Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2.

Authors:  Sugunadevi Sakkiah; Sundarapandian Thangapandian; Keun Woo Lee
Journal:  J Mol Model       Date:  2012-01-18       Impact factor: 1.810

6.  Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.

Authors:  Miao Yu; Qiong Gu; Jun Xu
Journal:  J Comput Aided Mol Des       Date:  2018-01-06       Impact factor: 3.686

7.  Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.

Authors:  Sugunadevi Sakkiah; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2012-06-11       Impact factor: 6.150

8.  Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer.

Authors:  Priyanka Verma; Md Imtaiyaz Hassan; Archana Singh; Indrakant K Singh
Journal:  Mol Cell Biochem       Date:  2021-03-26       Impact factor: 3.396

9.  3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.

Authors:  Vikas Kumar; Shraddha Parate; Amir Zeb; Pooja Singh; Gihwan Lee; Tae Sung Jung; Keun Woo Lee; Min Woo Ha
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

10.  Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.

Authors:  Raj Kumar; Minky Son; Rohit Bavi; Yuno Lee; Chanin Park; Venkatesh Arulalapperumal; Guang Ping Cao; Hyong-ha Kim; Jung-keun Suh; Yong-seong Kim; Yong Jung Kwon; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.